These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 20883287

  • 1. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
    Yilmaz M, Nart A, Sen S, Tasli F, Uslu A, Hur E, Ozkahya M, Hoscoskun C, Toz H.
    Nephrology (Carlton); 2010 Sep; 15(6):653-8. PubMed ID: 20883287
    [Abstract] [Full Text] [Related]

  • 2. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK, Weir MR.
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [Abstract] [Full Text] [Related]

  • 3. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 4. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 5. Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.
    Barbari A, Maawad M, Kfoury Kassouf H, Kamel G.
    Exp Clin Transplant; 2015 Oct; 13(5):377-86. PubMed ID: 26450460
    [Abstract] [Full Text] [Related]

  • 6. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 7. Histopathologic evaluation of pretransplantation biopsy as a factor influencing graft function after kidney transplantation in 3-year observation.
    Sulikowski T, Tejchman K, Ziętek Z, Urasińska E, Domański L, Sieńko J, Romanowski M, Safranow K, Zukowski M, Ciechanowicz A, Ciechanowski K, Ostrowski M.
    Transplant Proc; 2010 Nov; 42(9):3375-81. PubMed ID: 21094782
    [Abstract] [Full Text] [Related]

  • 8. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V.
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [Abstract] [Full Text] [Related]

  • 9. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B, Canver B, Gurlek Demirci B, Colak T, Ozdemir BH, Haberal M.
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [Abstract] [Full Text] [Related]

  • 10. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V, Abraham G, Fathima N, Sundaram V, Reddy YN, Mathew M, Sathiah V.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
    [Abstract] [Full Text] [Related]

  • 11. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
    Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G.
    Transplantation; 2008 Jan 15; 85(1):125-34. PubMed ID: 18192922
    [Abstract] [Full Text] [Related]

  • 12. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan 15; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 14. Ten-year protocol biopsy findings of renal allografts in the calcineurin inhibitor era.
    Okamoto M, Akioka K, Ushigome H, Higuchi A, Nobori S, Ogino S, Uryuhara K, Kaihara S, Hatta T, Urasaki K, Yoshimura N.
    Clin Transplant; 2006 Feb 15; 20 Suppl 15():16-9. PubMed ID: 16848870
    [Abstract] [Full Text] [Related]

  • 15. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Feb 15; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 16. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 17. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 18. Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi.
    Becker LE, Weritz B, Yi X, Gross-Weissmann ML, Waldherr R, Zeier M, Sommerer C.
    Transpl Int; 2015 May 27; 28(5):553-64. PubMed ID: 25630217
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP.
    Nephrology (Carlton); 2010 Apr 27; 15(3):368-76. PubMed ID: 20470309
    [Abstract] [Full Text] [Related]

  • 20. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J, Bridson JM, Sharma A, Halawa A.
    Exp Clin Transplant; 2017 Jun 27; 15(3):241-252. PubMed ID: 27915965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.